The Science Behind CartiNova

Most physicians will tell you that cartilage doesn’t heal. They’re not wrong about the biology — but they are behind on what technology now makes possible.

Cartilage is avascular. It has no blood supply of its own. Unlike muscle, bone, or skin, it can’t recruit the body’s repair machinery through the bloodstream after an injury. It relies on slow nutrient diffusion from synovial fluid, a process utterly inadequate for meaningful regeneration of cartilage lesions or degenerative changes. This is why cartilage damage has been considered essentially permanent — and why “you need a joint replacement” has been the default endpoint for so many patients.

The CartiNova procedure changes this by combining two technologies that, individually, have value — but together, unlock something neither can accomplish alone: Regenelase fractional laser energy that physically restructures the cartilage environment, paired with concentrated autologous biologics that deliver the body’s own healing factors directly into that restructured tissue. Here’s the science behind how it works.

The Cartilage Problem: Why Biology Can’t Fix This Alone

To understand why the CartiNova approach works, you need to understand what conventional medicine is working against.

Articular cartilage — the smooth, white tissue that cushions the ends of your bones in joints like the knee, hip, and shoulder — exists in a physiologically isolated environment. When it degrades from injury, overuse, or aging, the body has almost no mechanism to rebuild it. The few chondrocytes (cartilage cells) that remain in damaged tissue have limited proliferative capacity. They can’t replicate meaningfully enough to fill a lesion. And without a blood supply, the growth factors that normally orchestrate healing after injury — platelet-derived growth factor, TGF-β, VEGF — simply don’t arrive in concentrations sufficient to drive repair.

What does arrive, eventually, is fibrocartilage — a scar-tissue analog that lacks the mechanical properties of true hyaline cartilage. It’s softer, less durable, and prone to further degeneration. Microfracture surgery, which has been performed for decades, attempts to trigger healing by drilling through the subchondral bone to recruit marrow cells. What grows is primarily fibrocartilage. It’s better than nothing, but it’s not what the joint actually needs.

The Regenelase Laser: How Fractional Technology Enters Cartilage

The Regenelase is a dual-laser system developed for musculoskeletal soft tissue. It operates at two distinct wavelengths, each serving a different biological role:

• 1550 nm erbium fiber laser (internal): Delivered via a 400-micron optical fiber threaded through an 18-gauge cannula — a standard injection needle — under image guidance. When the fiber tip contacts target cartilage, it delivers a precisely controlled burst of energy in approximately 50 seconds, creating a grid of microscopic zones of thermal coagulation within the tissue.
• 980 nm diode laser (external): Applied to the surface of the skin overlying the treated joint as a follow-up procedure. At this wavelength, the laser penetrates to deep tissue, delivering photobiomodulation (PBM) therapy that elevates tissue temperature, modulates local inflammation, reduces pain, and increases circulation to prepare the surrounding tissue for healing.

Together, they treat the joint from the inside out (fractional fiber laser creating channels in cartilage) and the outside in (photobiomodulation activating the surrounding tissue and preparing biologics). This dual approach addresses the joint environment comprehensively — not just the cartilage surface.

Three Mechanisms: What the Laser Is Actually Doing

When the 1550 nm laser contacts cartilage, it doesn’t ablate or remove tissue. It creates nanopores — microscopic channels in the extracellular matrix — through three simultaneous mechanisms confirmed by atomic force microscopy in animal studies:

The result is a structurally modified cartilage environment that is biologically active, receptive to healing factors, and capable of integration with newly delivered biologics. Histological analysis from animal studies has shown that this fractional coagulative treatment can generate hyaline-like cartilage in chondromalacia — the type of cartilage most similar to what was lost, not the fibrocartilage scar that most healing modalities produce.

The Biologics Layer: PRP, BMAC, and MFAT

Once the Regenelase laser has prepared the cartilage environment, the second layer of the CartiNova procedure delivers concentrated autologous biologics under image guidance — directly into the nanopore-modified tissue. Three primary biologic options are used based on the degree of degeneration and the patient’s BioProfile:

The CartiNova Procedure: Step by Step

Clinical Evidence: What the Data Shows

The Regenelase system has been evaluated in multiple clinical settings. Key findings from published and presented data:

• 90% of patients in clinical studies of knee osteoarthritis treated with the Regenelase fractional laser showed improved pain and function at both 6 and 12 months follow-up, with no side effects reported.
• MRI follow-up in patients treated at CartiNova has shown objective evidence of new cartilage growth within six months — the kind of structural change that “non-surgical” options have historically been unable to demonstrate.
• Atomic force microscopy in animal studies confirmed nanopore formation in laser-treated cartilage, with histological analysis showing hyaline-like cartilage regeneration — not the fibrocartilage scar that microfracture and other older techniques produce.
• Significant improvement across pain, emotional well-being, and general health scores at 12-month follow-up in knee OA patients, including resolution of bone marrow edema and improved cartilage thickness in some cases.

A real-world example that illustrates the clinical potential: a long-distance runner diagnosed with severe arthritis and told she would never run again underwent the CartiNova procedure and reported running 10 miles pain-free within three weeks of treatment. While outcomes vary by patient and degree of degeneration, this case reflects what the combination of laser-prepared cartilage and concentrated biologics can achieve in the right candidate.

Who Is a Candidate for CartiNova?

The CartiNova procedure is designed for patients who are in the gap between “take an anti-inflammatory and wait” and “you need surgery” — a gap that standard orthopedic care often ignores. Conditions we treat include:

• Knee cartilage lesions and osteoarthritis (mild to advanced, including cases where other physicians have recommended replacement)
• Lumbar disc degeneration and facet arthropathy
• Sports-related cartilage injuries in active patients who want to preserve long-term joint function
• Degenerative joint conditions in other major joints where image-guided delivery is feasible
• Post-surgical augmentation, to support healing after arthroscopic repair

Patients with active joint infection, severe coagulopathy, or truly end-stage bone-on-bone disease may not be appropriate candidates. An individual consultation including imaging review is the appropriate first step — candidacy depends on the specific anatomy, degree of degeneration, and individual BioProfile, not a blanket diagnosis.

Frequently Asked Questions